Liraglutide, a GLP-1 analog, has been shown to enhance autophagy, providing protection to pancreatic β cells (53, 54) and potential treatment for conditions such as diabetic nephropathy and diabetic hepatopathy. This evidence concerns the gene GLP1R and diabetic kidney disease.